Opus Genetics (IRD) Shares Outstanding (Diluted Average) (2016 - 2026)

Opus Genetics (IRD) has 10 years of Shares Outstanding (Diluted Average) data on file, last reported at $86.9 million in Q1 2026.

• Quarterly Shares Outstanding (Diluted Average) rose 156.43% year-over-year to $86.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.9 million (up 156.43% YoY) and the FY2025 annual result came in at $62.2 million, up 132.91% from the prior year.
• Shares Outstanding (Diluted Average) climbed to $86.9 million in Q1 2026 per IRD's latest filing, from $62.2 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $86.9 million in Q1 2026 and bottomed at $18.9 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $25.8 million (2024), against an average of $35.1 million.
• The widest annual swing landed in 2023, when Shares Outstanding (Diluted Average) advanced 9.13%; it then soared 170.17% in 2025.
• Tracing IRD's Shares Outstanding (Diluted Average) over 5 years: stood at $19.6 million in 2022, then increased by 9.95% to $21.6 million in 2023, then rose by 23.74% to $26.7 million in 2024, then soared by 132.91% to $62.2 million in 2025, then surged by 39.65% to $86.9 million in 2026.
• Per Business Quant, the three latest IRD Shares Outstanding (Diluted Average) figures stand at $86.9 million (Q1 2026), $62.2 million (Q4 2025), and $70.6 million (Q3 2025).

Peer Comparison